FDA Designates Boston Scientific Imager II Angiographic Catheter Recall as Class I in September 2026: Sub-Specification Tip Stabilizer May Cause Detachment

What Happened

On August 24, 2026, Boston Scientific notified affected customers and requested that all Imager II Angiographic Catheters be withdrawn from points of use or sale. The U.S. Food and Drug Administration (FDA) subsequently classified the action as a Class I recall, the most serious category; the notice states that continued use of the product may cause serious injury or death.

The FDA Medical Device Recalls and Early Alerts listing shows a publication date of September 25, 2026, corresponding to Medical Device Recall Database Event 99687. The company notice came first and the FDA public classification followed, so the two dates differ and are identified separately below.

Affected Products

Imager II Angiographic Catheters are sterile, single-use diagnostic intravascular catheters supplied in a range of shapes and lengths, intended for imaging specific regions of interest in peripheral vessels. The company requested withdrawal of all Imager II Angiographic Catheters; no specific model or lot was limited.

One operational detail is easily overlooked. Healthcare facilities frequently remove the product from the outer carton and keep only the inner pouch on the shelf. In relaying the company notice, the FDA specifically notes that the UPN codes on the inner and outer packaging are not the same, so when screening for affected product both the inner and outer UPN must be checked. The Response Verification Tracking Form (RVTF) returned by the company lists only the outer packaging code, and that code governs when returns are reported. The product is distributed in 5-unit packs; when reporting quantities returned, the actual number of individual units must be stated, not the number of boxes or packs.

Cause and Risk

According to the company explanation relayed in the FDA notice, the issue originates in the manufacturing of the catheter tip: the stabilizer used in the tips of this batch was below the specified level, which may increase the risk of tip degradation and detachment. The company states that no increase in tip detachment complaints has been observed in the affected lots, but that these devices were manufactured outside the approved design specifications and were therefore withdrawn from the market; the company has also decided to discontinue sale of the product.

The notice also sets out an assessment of the magnitude of the risk. When a catheter tip detaches within a vessel, the most common consequence is the need to replace the device and a delay of the procedure; the notice states that this consequence may occur with a probability of each time the device is used. The most serious potential consequence is a life-threatening embolism within the vessel, in which device fragments block blood flow and cause end-organ failure, although the notice classifies this as a very low-probability scenario. As of July 16, 2026, the company had reported 2 serious injuries and 0 deaths associated with this issue.

Required Customer Actions

• Immediately stop further use or distribution of the affected product and quarantine it.
• Continue to monitor patients in whom the product has already been used, in accordance with the standard of care.
• Complete and return the enclosed RVTF.
• Verify UPNs against the product list.
• Return the product to Boston Scientific.
• Forward the notice to relevant personnel within the facility and to other facilities to which the product may have been distributed.

Sources, Verification Scope and Applicability

Sources: U.S. Food and Drug Administration (FDA) — Angiographic Catheter Recall: Boston Scientific Removes Imager II Angiographic Catheters, published September 25, 2026, https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/angiographic-catheter-recall-boston-scientific-removes-imager-ii-angiographic-catheters; FDA Medical Device Recalls and Early Alerts listing page, https://www.fda.gov/medical-devices/medical-device-safety/medical-device-recalls-and-early-alerts; FDA Medical Device Recall Database, Event 99687, https://www.accessdata.fda.gov/scripts/ires/index.cfm?Event=99687; FDA Medical Device Recalls and Early Alerts, https://www.fda.gov/medical-devices/medical-device-safety/medical-device-recalls-and-early-alerts.

Verification scope and access date: The FDA recall notice page, the Recalls and Early Alerts listing page and the recall database entry referenced above were reviewed on October 11, 2026.

Applicability: This article is an interpretation of publicly available FDA recall information and does not constitute a conclusion or commitment regarding any specific product, company or registration application. Details are governed by the official text, and information may change with subsequent official updates.

AIMEILI Regulatory Interpretation

The decisive regulatory fact in this case is not the complaint rate but the manufacturing status of the devices: the tips were produced with stabilizer below the specified level and the devices were therefore made outside the approved design specifications. Under FDA requirements, a device that does not conform to its specifications may be considered adulterated or misbranded regardless of whether complaints have increased. A firm-initialed removal that FDA later places in Class I indicates that the agency judged the potential health consequence to be of the highest severity, even though no deaths and only two serious injuries had been reported as of July 16, 2026.

For manufacturers, several compliance threads converge in this single event.

• Specification control at component level. A raw-material or process parameter such as stabilizer content in the catheter tip must remain within validated limits. Incoming inspection, supplier certificates of analysis, supplier change control and process validation records are the evidence base FDA will examine when deciding whether a deviation is an isolated lapse or a systemic weakness.
• Risk classification and hazard analysis. FDA health risk assessments drive Class I, II or III designation. Companies should be prepared to defend their own severity and probability determinations with material data, complaint trending and clinical hazard analysis, because the agency may reach a more severe conclusion.
• Reporting and field action obligations. A correction or removal initiated to reduce a health risk generally requires a Correction and Removal Report under 21 CFR 806, and serious injuries associated with the issue fall under Medical Device Reporting requirements in 21 CFR 803. Recall effectiveness checks, quantity reconciliation and formal closure remain mandatory even when the company decides to discontinue the product line.
• Packaging and identification integrity. The discrepancy between inner and outer UPNs is a practical traceability issue. Companies should include both packaging levels in recall notifications, product lists and tracking forms, and should verify that UDI and labelling systems support identification at the unit level as well as the carton level. Distributors and hospital materials management teams should build both checks into their quarantine procedures.
• Cross-border implications. A U.S. Class I recall is frequently referenced by other regulators and by notified bodies when reviewing vigilance, post-market surveillance and conformity assessment files. Registrants holding approvals in other jurisdictions should assess whether equivalent field safety corrective action notifications are required, and should retain the full recall file for inspections, renewals and audits.
• Quality system linkage. The event should be connected through CAPA to risk management under ISO 14971, design and process validation, supplier management and post-market surveillance activities, so that the corrective action closes the underlying cause rather than only the affected stock.

Business Impact

For distributors and healthcare facilities, the immediate impact is operational: unit-level stock reconciliation, quarantine of both inner pouches and outer cartons, completion and return of RVTFs, coordination of returns and credits, and continued clinical follow-up of patients already treated. Because the product is distributed in 5-unit packs but reported in single units, mismatches in returned quantities are likely unless receiving and reporting processes are aligned, and reconciliation discrepancies can delay recall closure.

For manufacturers in the angiographic and peripheral vascular catheter segment, the recall puts supplier qualification, tip bonding and material specifications under heightened scrutiny. Comparable product lines may face additional questions during inspections, audits and registration reviews, particularly where stabilizer content, tip integrity or lot-level material data are documented. Companies should review whether their own specifications, incoming testing and supplier change notifications would detect a comparable drift early enough to prevent a field action.

Commercially, the discontinuation of the Imager II line removes a product from the market and creates a supply gap that distributors and hospital purchasing teams must fill through alternative devices, with associated re-evaluation of equivalent products. The cost of a Class I recall typically includes retrieval logistics, replacement or credit processing, administrative handling of tracking forms, effectiveness checks, regulatory follow-up and potential legal or reimbursement exposure, all of which can exceed the value of the affected inventory. Regulatory affairs teams should treat the recall record as a controlled document for future submissions, inspections and vigilance reporting in all markets where the device is registered.